Mibefradil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mibefradil
Mibefradil.png
Systematic (IUPAC) name
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a607007
Legal status Withdrawn from market
Routes Oral
Identifiers
CAS number 116644-53-2 YesY
ATC code C08CX01
PubChem CID 60662
DrugBank DB01388
ChemSpider 54673 N
UNII 27B90X776A N
KEGG D08217 YesY
ChEMBL CHEMBL45816 N
Chemical data
Formula C29H38FN3O3 
Mol. mass 495.63 g/mol
 N (what is this?)  (verify)

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

It is nonselective.[1]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]

References[edit]